Eligibility criteria
Condition
Erectile Dysfunction
Sex
Male
Age
18 + years
Inclusion criteria
Show details
- CV risk factors
- Male above 18
Exclusion criteria
Show details
- Non-informed consent
You are here
Satisfaction With Phosphodiesterase 5 Inhibitors Treatment In Patients With Cardiovascular Risk
NCT00874185
Last updated on November 14, 2019
About this Study
Evaluate satisfaction in people treated with IPDE5 inhibitors over time
NCT00874185
Pfizer
Completed
Satisfaction With Phosphodiesterase 5 Inhibitors Treatment In Patients With Cardiovascular Risk
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative
| Descriptive Information | ||||
|---|---|---|---|---|
| Brief Title | Satisfaction With Phosphodiesterase 5 Inhibitors Treatment In Patients With Cardiovascular Risk | |||
| Official Title | Satisfaction With Treatment In Patients With Erectile Dysfunction And Cardiovascular Risk And/Or Previous Cardiovascular Event. | |||
| Brief Summary | Evaluate satisfaction in people treated with IPDE5 inhibitors over time | |||
| Detailed Description | 12 first patients that are eligible | |||
| Study Type | Observational | |||
| Study Design | Observational Model: Cohort Time Perspective: Prospective | |||
| Target Follow-Up Duration | Not Provided | |||
| Biospecimen | Not Provided | |||
| Sampling Method | Non-Probability Sample | |||
| Study Population | People with cv risk | |||
| Condition | Erectile Dysfunction | |||
| Intervention | Not Provided | |||
| Study Groups/Cohorts | Questionnaire filling in questionnaires | |||
| Publications * | Not Provided | |||
| * Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | ||||
| Recruitment Information | ||||
| Recruitment Status | Completed | |||
| Actual Enrollment | 720 | |||
| Original Actual Enrollment | 572 | |||
| Actual Study Completion Date | May 2008 | |||
| Actual Primary Completion Date | May 2008 (Final data collection date for primary outcome measure) | |||
| Eligibility Criteria | Inclusion Criteria:
Exclusion Criteria:
| |||
| Sex/Gender |
| |||
| Ages | 18 Years and older (Adult, Older Adult) | |||
| Accepts Healthy Volunteers | No | |||
| Contacts | Contact information is only displayed when the study is recruiting subjects | |||
| Listed Location Countries | Not Provided | |||
| Removed Location Countries | ||||
| Administrative Information | ||||
| NCT Number | NCT00874185 | |||
| Other Study ID Numbers | A1481256 A1481256 | |||
| Has Data Monitoring Committee | No | |||
| U.S. FDA-regulated Product | Not Provided | |||
| IPD Sharing Statement | Not Provided | |||
| Responsible Party | Pfizer | |||
| Study Sponsor | Pfizer | |||
| Collaborators | Not Provided | |||
| Investigators |
| |||
| PRS Account | Pfizer | |||
| Verification Date | February 2013 | |||
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
BY PHONE
Pfizer Clinical Trials Contact Center
1-800-718-1021